UroGen Pharma (NASDAQ:URGN) Issues Earnings Results, Misses Expectations By $0.11 EPS

UroGen Pharma (NASDAQ:URGN) issued its quarterly earnings results on Monday. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11), Zacks reports.

UroGen Pharma Stock Down 0.8 %

Shares of NASDAQ:URGN opened at $9.75 on Monday. The stock has a market capitalization of $228.56 million, a P/E ratio of -3.09 and a beta of 1.12. The stock has a 50-day simple moving average of $10.45 and a 200-day simple moving average of $11.76. UroGen Pharma has a 1 year low of $9.03 and a 1 year high of $20.70. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00.

Insider Transactions at UroGen Pharma

In related news, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the sale, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares in the company, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on URGN. LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target on the stock. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a report on Tuesday, February 18th. Finally, HC Wainwright reissued a “buy” rating and set a $64.00 price target on shares of UroGen Pharma in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $40.00.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.